Skip to Main Content

WASHINGTON — The Food and Drug Administration has been without a permanent commissioner for six months. The agency is facing a barrage of criticisms over its approval of an as-yet-unproven Alzheimer’s drug. And now critics are calling for the ouster of the acting commissioner.

But speaking to that acting FDA Commissioner, longtime agency vet Janet Woodcock, you’d think everything is peachy.


In a phone call with STAT on Wednesday, Woodcock emphasized that the lack of a permanent commissioner is not hampering the agency’s operations, and that she has the full support of the administration to pursue whatever policies she deems fit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.